Skip to main content
Premium Trial:

Request an Annual Quote

Scipher Medicine Raises Series B Financing Total to $25M

NEW YORK – Scipher Medicine said on Wednesday that it has completed a second close in its previously announced Series B financing round, raising its total to $25 million with a new investment from Optum Ventures.

Based in Waltham, Massachusetts, Scipher is developing molecular tests to aid in therapeutic decision-making in the autoimmune disease space, using a proprietary approach for discovering RNA signatures. The first of these assays is PrismRA, a test to predict response to anti-tumor necrosis (anti-TNF) therapies in rheumatoid arthritis patients.

According to the company, Optum Ventures' investment, along with other Series B investments, will help accelerate its work on PrismRA and further its expansion into other difficult-to-treat and complex disease areas.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.